Rationale for developing a specimen bank to study the pathogenesis of high-grade serous carcinoma

A review of the evidence

Mark E. Sherman, Ronny I. Drapkin, Neil S. Horowitz, Christopher P. Crum, Sue Friedman, Janice S. Kwon, Douglas A. Levine, Ie Ming Shih, Donna Shoupe, Elizabeth M. Swisher, Joan Walker, Britton Trabert, Mark H. Greene, Goli Samimi, Sarah M. Temkin, Lori M. Minasian

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Women with clinically detected high-grade serous carcinomas (HGSC) generally present with advanced-stage disease, which portends a poor prognosis, despite extensive surgery and intensive chemotherapy. Historically, HGSCs were presumed to arise from the ovarian surface epithelium (OSE), but the inability to identify early-stage HGSCs and their putative precursors in the ovary dimmed prospects for advancing our knowledge of the pathogenesis of these tumors and translating these findings into effective prevention strategies. Over the last decade, increased BRCA1/2 mutation testing coupled with performance of risk-reducing surgeries has enabled studies that have provided strong evidence that many, but probably not all, HGSCs among BRCA1/2 mutation carriers appear to arise from the fallopian tubes, rather than from the ovaries. This shift in our understanding of the pathogenesis of HGSCs provides an important opportunity to achieve practice changing advances; however, the scarcity of clinically annotated tissues containing early lesions, particularly among women at average risk, poses challenges to progress. Accordingly, we review studies that have kindled our evolving understanding of the pathogenesis of HGSC and present the rationale for developing an epidemiologically annotated national specimen resource to support this research.

Original languageEnglish (US)
Pages (from-to)713-720
Number of pages8
JournalCancer Prevention Research
Volume9
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Ovary
Carcinoma
Mutation
Fallopian Tubes
Epithelium
Drug Therapy
Research
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rationale for developing a specimen bank to study the pathogenesis of high-grade serous carcinoma : A review of the evidence. / Sherman, Mark E.; Drapkin, Ronny I.; Horowitz, Neil S.; Crum, Christopher P.; Friedman, Sue; Kwon, Janice S.; Levine, Douglas A.; Shih, Ie Ming; Shoupe, Donna; Swisher, Elizabeth M.; Walker, Joan; Trabert, Britton; Greene, Mark H.; Samimi, Goli; Temkin, Sarah M.; Minasian, Lori M.

In: Cancer Prevention Research, Vol. 9, No. 9, 01.09.2016, p. 713-720.

Research output: Contribution to journalReview article

Sherman, ME, Drapkin, RI, Horowitz, NS, Crum, CP, Friedman, S, Kwon, JS, Levine, DA, Shih, IM, Shoupe, D, Swisher, EM, Walker, J, Trabert, B, Greene, MH, Samimi, G, Temkin, SM & Minasian, LM 2016, 'Rationale for developing a specimen bank to study the pathogenesis of high-grade serous carcinoma: A review of the evidence', Cancer Prevention Research, vol. 9, no. 9, pp. 713-720. https://doi.org/10.1158/1940-6207.CAPR-15-0384
Sherman, Mark E. ; Drapkin, Ronny I. ; Horowitz, Neil S. ; Crum, Christopher P. ; Friedman, Sue ; Kwon, Janice S. ; Levine, Douglas A. ; Shih, Ie Ming ; Shoupe, Donna ; Swisher, Elizabeth M. ; Walker, Joan ; Trabert, Britton ; Greene, Mark H. ; Samimi, Goli ; Temkin, Sarah M. ; Minasian, Lori M. / Rationale for developing a specimen bank to study the pathogenesis of high-grade serous carcinoma : A review of the evidence. In: Cancer Prevention Research. 2016 ; Vol. 9, No. 9. pp. 713-720.
@article{cce97fdcfd894abe80dacfc01a8f649e,
title = "Rationale for developing a specimen bank to study the pathogenesis of high-grade serous carcinoma: A review of the evidence",
abstract = "Women with clinically detected high-grade serous carcinomas (HGSC) generally present with advanced-stage disease, which portends a poor prognosis, despite extensive surgery and intensive chemotherapy. Historically, HGSCs were presumed to arise from the ovarian surface epithelium (OSE), but the inability to identify early-stage HGSCs and their putative precursors in the ovary dimmed prospects for advancing our knowledge of the pathogenesis of these tumors and translating these findings into effective prevention strategies. Over the last decade, increased BRCA1/2 mutation testing coupled with performance of risk-reducing surgeries has enabled studies that have provided strong evidence that many, but probably not all, HGSCs among BRCA1/2 mutation carriers appear to arise from the fallopian tubes, rather than from the ovaries. This shift in our understanding of the pathogenesis of HGSCs provides an important opportunity to achieve practice changing advances; however, the scarcity of clinically annotated tissues containing early lesions, particularly among women at average risk, poses challenges to progress. Accordingly, we review studies that have kindled our evolving understanding of the pathogenesis of HGSC and present the rationale for developing an epidemiologically annotated national specimen resource to support this research.",
author = "Sherman, {Mark E.} and Drapkin, {Ronny I.} and Horowitz, {Neil S.} and Crum, {Christopher P.} and Sue Friedman and Kwon, {Janice S.} and Levine, {Douglas A.} and Shih, {Ie Ming} and Donna Shoupe and Swisher, {Elizabeth M.} and Joan Walker and Britton Trabert and Greene, {Mark H.} and Goli Samimi and Temkin, {Sarah M.} and Minasian, {Lori M.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1158/1940-6207.CAPR-15-0384",
language = "English (US)",
volume = "9",
pages = "713--720",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Rationale for developing a specimen bank to study the pathogenesis of high-grade serous carcinoma

T2 - A review of the evidence

AU - Sherman, Mark E.

AU - Drapkin, Ronny I.

AU - Horowitz, Neil S.

AU - Crum, Christopher P.

AU - Friedman, Sue

AU - Kwon, Janice S.

AU - Levine, Douglas A.

AU - Shih, Ie Ming

AU - Shoupe, Donna

AU - Swisher, Elizabeth M.

AU - Walker, Joan

AU - Trabert, Britton

AU - Greene, Mark H.

AU - Samimi, Goli

AU - Temkin, Sarah M.

AU - Minasian, Lori M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Women with clinically detected high-grade serous carcinomas (HGSC) generally present with advanced-stage disease, which portends a poor prognosis, despite extensive surgery and intensive chemotherapy. Historically, HGSCs were presumed to arise from the ovarian surface epithelium (OSE), but the inability to identify early-stage HGSCs and their putative precursors in the ovary dimmed prospects for advancing our knowledge of the pathogenesis of these tumors and translating these findings into effective prevention strategies. Over the last decade, increased BRCA1/2 mutation testing coupled with performance of risk-reducing surgeries has enabled studies that have provided strong evidence that many, but probably not all, HGSCs among BRCA1/2 mutation carriers appear to arise from the fallopian tubes, rather than from the ovaries. This shift in our understanding of the pathogenesis of HGSCs provides an important opportunity to achieve practice changing advances; however, the scarcity of clinically annotated tissues containing early lesions, particularly among women at average risk, poses challenges to progress. Accordingly, we review studies that have kindled our evolving understanding of the pathogenesis of HGSC and present the rationale for developing an epidemiologically annotated national specimen resource to support this research.

AB - Women with clinically detected high-grade serous carcinomas (HGSC) generally present with advanced-stage disease, which portends a poor prognosis, despite extensive surgery and intensive chemotherapy. Historically, HGSCs were presumed to arise from the ovarian surface epithelium (OSE), but the inability to identify early-stage HGSCs and their putative precursors in the ovary dimmed prospects for advancing our knowledge of the pathogenesis of these tumors and translating these findings into effective prevention strategies. Over the last decade, increased BRCA1/2 mutation testing coupled with performance of risk-reducing surgeries has enabled studies that have provided strong evidence that many, but probably not all, HGSCs among BRCA1/2 mutation carriers appear to arise from the fallopian tubes, rather than from the ovaries. This shift in our understanding of the pathogenesis of HGSCs provides an important opportunity to achieve practice changing advances; however, the scarcity of clinically annotated tissues containing early lesions, particularly among women at average risk, poses challenges to progress. Accordingly, we review studies that have kindled our evolving understanding of the pathogenesis of HGSC and present the rationale for developing an epidemiologically annotated national specimen resource to support this research.

UR - http://www.scopus.com/inward/record.url?scp=84987923878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987923878&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-15-0384

DO - 10.1158/1940-6207.CAPR-15-0384

M3 - Review article

VL - 9

SP - 713

EP - 720

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 9

ER -